Significantly More Weight Loss Seen With Tirzepatide Versus Semaglutide
By Elana Gotkine HealthDay Reporter
MONDAY, July 8, 2024 -- Tirzepatide is associated with significantly greater weight loss than semaglutide for adults with overweight or obesity, according to a study published online July 8 in JAMA Internal Medicine.
Patricia J. Rodriguez, Ph.D., from Truveta Inc. in Bellevue, Washington, and colleagues compared on-treatment weight loss and rates of gastrointestinal adverse events among adults with overweight or obesity receiving tirzepatide or semaglutide labeled for type 2 diabetes. After propensity score matching, 18,386 adults were included in the study.
The researchers found that participants receiving tirzepatide were significantly more likely to achieve weight loss than those receiving semaglutide (≥5, ≥10, and ≥15 percent weight loss hazard ratios: 1.76, 2.54, and 3.24, respectively). For patients receiving tirzepatide, on-treatment changes in weight were larger at three, six, and 12 months (differences, −2.4, −4.3, and −6.9 percent, respectively). The groups had similar rates of gastrointestinal adverse events.
"Individuals with overweight or obesity treated with tirzepatide were significantly more likely to achieve clinically meaningful weight loss and larger reductions in body weight compared with those treated with semaglutide," the authors write. "Consistent treatment effect estimates were observed in subgroups with and without type 2 diabetes."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted July 2024
Read this next
Adverse Pregnancy Outcomes Partly Mediate Association Between Prepregnancy Obesity, CVD Risk
MONDAY, April 21, 2025 -- Adverse pregnancy outcomes (APOs) mediate a small proportion of the association between prepregnancy obesity and cardiovascular disease (CVD) risk in...
Tirzepatide Dispensations Increased Rapidly After Approval
TUESDAY, April 15, 2025 -- After approval, tirzepatide dispensations increased markedly among adults with type 2 diabetes prescribed glucose-lowering medications (GLMs) and among...
Adverse Events From Semaglutide Seen in the ED Usually GI-Related
TUESDAY, April 15, 2025 -- The rate of emergency department visits for adverse events among patients dispensed semaglutide is low, with most visits involving gastrointestinal...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.